EUVIMEDEUVIMED entdecken
Multizentrische Studie

Real‐world performance of Uromonitor® in urothelial bladder cancer detection: a multicentric trial

Ingmar Wolff, Anton P Kravchuk, Ralph M Wirtz, Thorsten Schlomm, Anja Rabien iD, Dezhi Rong, Sebastian L Hofbauer, Flora K Labonté, Dimitri Barski, Thomas Otto, Andreas Gössl, Sabine D Brookman-May und 3 weitere

BJU International · 2024

DOI: 10.1111/bju.16450 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift BJU International, 2024. Verfasst von Ingmar Wolff und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Medicine Greifswald, Greifswald, Germany. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Proto-Oncogene Mas, Receptor, Fibroblast Growth Factor, Type 3. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To compare Uromonitor® (U‐Monitor Lda, Porto, Portugal), a multitarget DNA assay that detects mutated proto‐oncogenes (telomerase reverse transcriptase [ TERT ], fibroblast growth factor receptor 3 [ FGFR‐3 ], Kirsten rat sarcoma viral oncogene homologue [ KRAS ]), with urine cytology in the urine‐based diagnosis of urothelial carcinoma of the bladder (UCB) within a multicentre real‐world setting. Patients and Methods This multicentre, prospective, double‐blind study was conducted across four German urological centres from 2019 to 2024. We evaluated the diagnostic performance of Uromonitor compared to urine cytology in a cohort of patients with UCB and in healthy controls within a real‐world setting. Sensitivity, specificity, positive‐predictive value (PPV), negative‐predictive value (NPV), and accuracy of the tests were measured, in addition to multivariate analyses to assess the ability of individual proto‐oncogene mutations in detecting UCB. The biometric sample size was designed to achieve a 10% difference in sensitivity.

Results

Patients with UCB comprised 63.7% (339/532) of the study group. Uromonitor showed a sensitivity, specificity, PPV, NPV, accuracy, and an area‐under‐the‐curve of 49.3%, 93.3%, 92.8%, 51.1%, 65.2%, and 0.713%, respectively. These metrics did not demonstrate statistical superiority over urine cytology in terms of sensitivity (44.6%; P = 0.316). Moreover, the comparison of additional test parameters, as well as the comparison within various sensitivity analyses, yielded no significant disparity between the two urinary tests. Multivariate logistic regression underscored the significant predictive value of a positive Uromonitor for detecting UCB (odds ratio [OR] 9.03; P < 0.001). Furthermore, mutations in TERT and FGFR‐3 were independently associated with high odds of UCB detection (OR 13.30 and 7.04, respectively), while KRAS mutations did not exhibit predictive capability.

Conclusion

Despite its innovative approach, Uromonitor fell short of confirming the superior results anticipated from previous studies in this real‐world setting. The search for an optimal urine‐based biomarker for detecting and monitoring UCB remains ongoing. Results from this study highlight the complexity of developing non‐invasive diagnostic tools and emphasise the importance of continued research efforts to refine these technologies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsProto-Oncogene MasReceptor, Fibroblast Growth Factor, Type 3HumansMaleFemaleAgedProspective StudiesMiddle AgedDouble-Blind MethodTelomeraseCarcinoma, Transitional CellProto-Oncogene Proteins p21(ras)Sensitivity and SpecificityMutationPredictive Value of TestsBiomarkers, TumorAged, 80 and over

Stichwörter der Autor:innen

FGFR‐3KRASTERTdiagnostic accuracymolecular biomarkerproto‐oncogenessensitivityurine cytology

Substanzen

Proto-Oncogene MasMAS1 protein, humanReceptor, Fibroblast Growth Factor, Type 3TelomeraseFGFR3 protein, humanTERT protein, humanProto-Oncogene Proteins p21(ras)KRAS protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, University Medicine Greifswald, Greifswald, Germany.
  • Department of Urology, St. Elisabeth Hospital Straubing, Brothers of Mercy Hospital, Straubing, Germany.
  • STRATIFYER Molecular Pathology GmbH, Cologne, Germany.
  • Department of Urology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Department of Urology, Rheinland Clinic Neuss, Neuss, Germany.
  • Medical School, University of Duisburg-Essen, Essen, Germany.

ORCID-Profile: Anja Rabien, Matthias May

Zitieren

APA

Wolff, I., Kravchuk, A. P., Wirtz, R. M., Schlomm, T., Rabien, A., Rong, D., Hofbauer, S. L., Labonté, F. K., Barski, D., Otto, T., Gössl, A., Brookman-May, S. D., Gilfrich, C. P., Ecke, T. H., & May, M. (2024). Real‐world performance of Uromonitor® in urothelial bladder cancer detection: a multicentric trial. BJU International. https://doi.org/10.1111/bju.16450

Vancouver

Wolff I, Kravchuk AP, Wirtz RM, Schlomm T, Rabien A, Rong D, et al. Real‐world performance of Uromonitor® in urothelial bladder cancer detection: a multicentric trial. BJU International. 2024. doi:10.1111/bju.16450

BibTeX
@article{Wolff2024,
  author = {Wolff, Ingmar and Kravchuk, Anton P and Wirtz, Ralph M and Schlomm, Thorsten and Rabien, Anja and Rong, Dezhi and Hofbauer, Sebastian L and Labonté, Flora K and Barski, Dimitri and Otto, Thomas and Gössl, Andreas and Brookman-May, Sabine D and Gilfrich, Christian P and Ecke, Thorsten H and May, Matthias},
  title = {Real‐world performance of Uromonitor® in urothelial bladder cancer detection: a multicentric trial},
  journal = {BJU International},
  year = {2024},
  doi = {10.1111/bju.16450}
}
Kostenlos starten →